Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Lowers Price Target to $107
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Lewis has maintained an Equal-Weight rating on Abbott Laboratories (NYSE:ABT) and lowered the price target from $112 to $107.
October 19, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Abbott Laboratories and lowered the price target from $112 to $107.
The lowering of the price target by Morgan Stanley could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100